As LC3II was also found to be significantly different, which was a biomarker of mTOR pathway mediated autophagic–lysosomal disorders, we hypothesized that this disorder might be associated with differing expression levels of CTLA-4 on CD4+ lymphocytes. This evidence concerns the gene MTOR and lysosomal storage disease.